Patent US2817038A successfully refreshed from Google Patents.
Patent US6049025A successfully refreshed from Google Patents.
US6049025A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Articular cartilage xenografts
Assignee: Drexel University
•
Filing: 1998-03-06
•
Granted: 2000-04-11
•
Expires: 2018-03-06
Abstract
Abstract The invention provides an article of manufacture comprising a substantially non-immunogenic articular cartilage xenograft for implantation into humans. The invention further provides a method for preparing an articular cartilage xenograft by removing at least a portion of an articular cartilage from a non-human animal to provide a xenograft; washing the xenograft in saline and alcohol; subjecting the xenograft to at least one treatment selected from the group consisting of exposure to ultraviolet radiation, immersion in alcohol, ozonation, freeze/thaw cycling, and optionally to chemical crosslinking. In addition to or in lieu of the above treatments, the methods include a cellular disruption treatment and either digestion of the carbohydrate moieties of the xenograft with a glycosidase in a range of about 1 mU/ml to about 1000 U/ml or glycosidase digestion followed by treatment for sialylation. The invention also provides articles of manufacture produced by one or more of the above-identified methods of the invention. The invention further provides an articular cartilage xenograft for implantation into a human including a portion of an articular cartilage from a non-human animal, wherein the portion includes extracellular matrix and substantially only dead cells. The matrix and dead cells have substantially no surface α-galactosyl moieties and have sialic acid linked to at least a portion of surface carbohydrate moieties. Each of the xenografts of the invention is substantially non-immunogenic and has substantially the same mechanical properties as the respective native articular cartilage.
Inventors
- 👤 Kevin R. Stone
- 👤 Uri Galili
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 16:55
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/36; A61L27/3683; A61L27/3687; A61F; A61F2/00; A61F2/02; A61F2/30; A61F2/30756; A61L27/3604; A61L27/3608; A61L27/3612; A61L27/3641; A61L27/3645; A61L27/3654; A61F2/3094; A61F2/38; A61F2/3859; A61F2/389
Claims Analysis
Total Claims: 41
Claim 1
Independent Claim
137 words
A method of preparing an articular cartilage xenograft for implantation into a human, which comprises a. removing at least a portion of an articular cartilage from a joint of a non-human animal to provide a xenograft; b. washing the xenograft in water and alcohol; c. subjecting the xenograft to a cellular disruption treatment; d. digesting the xenograft with a glycosidase to remove substantially a plurality of first surface carbohydrate moieties from the xenograft, wherein the glycosidase has a concentration in a range of about 1 mU/ml to about 1000 U/ml; and e. treating a plurality of second surface carbohydrate moieties on the xenograft with a plurality of capping molecules to cap at least a portion of the second surface carbohydrate moieties, whereby the xenograft is substantially non-immunogenic and has substantially the same mechanical properties as thearticular cartilage.
Claim 2
Independent Claim
137 words
A method of preparing an articular cartilage xenograft for implantation into a human, which comprises a. removing at least a portion of an articular cartilage from a joint of a non-human animal to provide a xenograft; b. washing the xenograft in water and alcohol; c. subjecting the xenograft to a cellular disruption treatment; d. digesting the xenograft with a glycosidase to remove substantially a plurality of first surface carbohydrate moieties from the xenograft, wherein the glycosidase has a concentration in a range of about 1 mU/ml to about 1000 U/ml; and e. treating a plurality of second surface carbohydrate moieties on the xenograft with a plurality of capping molecules to cap at least a portion of the second surface carbohydrate moieties, whereby the xenograft is substantially non-immunogenic and has substantially the same mechanical properties as thearticular cartilage.
Claim 3
Dependent Claim
37 words
The method of claim 1, wherein the capping step comprises treating the second surface carbohydrate moieties on the xenograft with the capping molecules having a concentration in a range of about 0.01 mM to about 100 mM.
Claim 4
Dependent Claim
18 words
The method of claim 1, wherein at least a portion of the capping molecules are sialic acid molecules.
Claim 5
Dependent Claim
11 words
The method of claim 1, wherein the glycosidase is a galactosidase.
Claim 6
Dependent Claim
11 words
The method of claim 4, wherein the galactosidase is an α-galactosidase.
Claim 7
Dependent Claim
13 words
The method of claim 1, wherein the cellular disruption treatment comprises freeze/thaw cycling.
Claim 8
Dependent Claim
15 words
The method of claim 1, wherein the cellular disruption treatment comprises exposure to gamma radiation.
Claim 9
Dependent Claim
19 words
The method of claim 1, wherein the removing step comprises removing with the portion a layer of subchondral bone.
Claim 10
Dependent Claim
24 words
The method of claim 1 further comprising the step of following step c, exposing the xenograft to a crosslinking agent in a vapor form.
Claim 11
Independent Claim
121 words
A method of preparing an articular cartilage xenograft for implantation into a human, which comprises a. removing at least a portion of an articular cartilage from a joint of a non-human animal to provide a xenograft; b. washing the xenograft in water and alcohol; c. subjecting the xenograft to a cellular disruption treatment; d. digesting the xenograft with a glycosidase to remove substantially a plurality of first surface carbohydrate moieties from the xenograft; and e. treating a plurality of second surface carbohydrate moieties on the xenograft with a plurality of sialic acid molecules to cap at least a portion of the surface carbohydrate moieties, whereby the xenograft is substantially non-immunogenic and has substantially the same mechanical properties as the articular cartilage.
Claim 12
Independent Claim
121 words
A method of preparing an articular cartilage xenograft for implantation into a human, which comprises a. removing at least a portion of an articular cartilage from a joint of a non-human animal to provide a xenograft; b. washing the xenograft in water and alcohol; c. subjecting the xenograft to a cellular disruption treatment; d. digesting the xenograft with a glycosidase to remove substantially a plurality of first surface carbohydrate moieties from the xenograft; and e. treating a plurality of second surface carbohydrate moieties on the xenograft with a plurality of sialic acid molecules to cap at least a portion of the surface carbohydrate moieties, whereby the xenograft is substantially non-immunogenic and has substantially the same mechanical properties as the articular cartilage.
Claim 13
Dependent Claim
38 words
The method of claim 10, wherein the capping step comprises treating the second surface carbohydrate moieties on the xenograft with the sialic acid molecules having a concentration in a range of about 0.01 mM to about 100 mM.
Claim 14
Dependent Claim
11 words
The method of claim 10, wherein the glycosidase is a galactosidase.
Claim 15
Dependent Claim
11 words
The method of claim 12, wherein the galactosidase is an α-galactosidase.
Claim 16
Dependent Claim
13 words
The method of claim 10, wherein the cellular disruption treatment comprises freeze/thaw cycling.
Claim 17
Dependent Claim
15 words
The method of claim 10, wherein the cellular disruption treatment comprises exposure to gamma radiation.
Claim 18
Dependent Claim
19 words
The method of claim 10, wherein the removing step comprises removing with the portion a layer of subchondral bone.
Claim 19
Dependent Claim
24 words
The method of claim 10 further comprising the step of following step c, exposing the xenograft to a crosslinking agent in a vapor form.
Claim 20
Dependent Claim
146 words
An article of manufacture comprising a substantially non-immunogenic knee articular cartilage xenograft for implantation in to a human, produced by a. removing at least a portion of an articular cartilage from a joint of a non-human animal to provide a xenograft; b. washing the xenoiraft in water and alcohol; c. subjecting the xenograft to a cellular disruption treatment; d. digesting the xenograft with a glycosidase to remove substantially a plurality of first surface carbohydrate moieties from the xenograft, wherein the glycosidase has a concentration in a range of about 1 mU/ml to about 1000 U/ml; and e. treating a plurality of second surface carbohydrate moieties on the xenograft with a plurality of capping molecules to cap at least a portion of the second surface carbohydrate moieties on the xenograft, whereby the xenograft is substantially non-immunogenic and has substantially the same mechanical properties as the articular cartilage.
Claim 21
Dependent Claim
146 words
An article of manufacture comprising a substantially non-immunogenic knee articular cartilage xenograft for implantation in to a human, produced by a. removing at least a portion of an articular cartilage from a joint of a non-human animal to provide a xenograft; b. washing the xenoiraft in water and alcohol; c. subjecting the xenograft to a cellular disruption treatment; d. digesting the xenograft with a glycosidase to remove substantially a plurality of first surface carbohydrate moieties from the xenograft, wherein the glycosidase has a concentration in a range of about 1 mU/ml to about 1000 U/ml; and e. treating a plurality of second surface carbohydrate moieties on the xenograft with a plurality of capping molecules to cap at least a portion of the second surface carbohydrate moieties on the xenograft, whereby the xenograft is substantially non-immunogenic and has substantially the same mechanical properties as the articular cartilage.
Claim 22
Dependent Claim
20 words
The article of manufacture of claim 18, wherein at least a portion of the capping molecules are sialic acid molecules.
Claim 23
Dependent Claim
14 words
The article of manufacture of claim 18, where in the glycosidase is a galactosidase.
Claim 24
Dependent Claim
13 words
The article of manufacture of claim 20, wherein the galactosidase is an α-galactosidase.
Claim 25
Dependent Claim
25 words
The article of manufacture of claim 19, wherein the capping molecules have a concentration in a range of about 0.01 mM to about 100 mM.
Claim 26
Dependent Claim
15 words
The article of manufacture of claim 18, wherein the cellular disruption treatment comprises freeze/thaw cycling.
Claim 27
Dependent Claim
17 words
The article of manufacture of claim 18, wherein the cellular disruption treatment comprises exposure to gamma radiation.
Claim 28
Dependent Claim
21 words
The article of manufacture of claim 18, wherein the removing step comprises removing with the portion a layer of subchondral bone.
Claim 29
Dependent Claim
26 words
The article of manufacture of claim 18 further comprising the step of following step c, exposing the xenograft to a crosslinking agent in a vapor form.
Claim 30
Dependent Claim
127 words
An article of manufacture comprising a substantially non-immunogenic knee articular cartilage xenograft for implantation in to a human, produced by a. removing at least a portion of an articular cartilage from a joint of a non-human animal to provide a xenograft; b. washing the xenograft in water and alcohol; c. subjecting the xenograft to a cellular disruption treatment; d. digesting the xenograft with a glycosidase to remove substantially a plurality of first surface carbohydrate moieties from the xenograft; and e. treating a plurality of second surface carbohydrate moieties on the xenograft with a plurality of sialic acid molecules to cap at least a portion of the second surface carbohydrate moieties, whereby the xenograft is substantially non-immunogenic and has substantially the same mechanical properties as the articular cartilage.
Claim 31
Dependent Claim
127 words
An article of manufacture comprising a substantially non-immunogenic knee articular cartilage xenograft for implantation in to a human, produced by a. removing at least a portion of an articular cartilage from a joint of a non-human animal to provide a xenograft; b. washing the xenograft in water and alcohol; c. subjecting the xenograft to a cellular disruption treatment; d. digesting the xenograft with a glycosidase to remove substantially a plurality of first surface carbohydrate moieties from the xenograft; and e. treating a plurality of second surface carbohydrate moieties on the xenograft with a plurality of sialic acid molecules to cap at least a portion of the second surface carbohydrate moieties, whereby the xenograft is substantially non-immunogenic and has substantially the same mechanical properties as the articular cartilage.
Claim 32
Dependent Claim
26 words
The article of manufacture of claim 27, wherein the sialic acid molecules have a concentration in a range of about 0.01 mM to about 100 mM.
Claim 33
Dependent Claim
13 words
The article of manufacture of claim 27, wherein the glycosidase is a galactosidase.
Claim 34
Dependent Claim
13 words
The article of manufacture of claim 29, wherein the galactosidase is an α-galactosidase.
Claim 35
Dependent Claim
15 words
The article of manufacture of claim 27, wherein the cellular disruption treatment comprises freeze/thaw cycling.
Claim 36
Dependent Claim
17 words
The article of manufacture of claim 27, wherein the cellular disruption treatment comprises exposure to gamma radiation.
Claim 37
Dependent Claim
21 words
The article of manufacture of claim 27, wherein the removing step comprises removing with the portion a layer of subchondral bone.
Claim 38
Dependent Claim
26 words
The article of manufacture of claim 27 further comprising the step of following step c, exposing the xenograft to a crosslinking agent in a vapor form.
Claim 39
Dependent Claim
96 words
An articular cartilage xenograft for implantation into a human comprising a portion of an articular cartilage from a joint of a non-human animal, wherein the portion includes an extracellular matrix and a plurality of substantially only dead cells, the extracellular matrix and the dead cells having substantially no surface α-galactosyl moieties and having a plurality of sialic acid molecules linked to at least a portion of a plurality of surface carbohydrate moieties on the xenograft, whereby the portion of the articular cartilage is substantially non-immunogenic and has substantially the same mechanical properties as the articular cartilage.
Claim 40
Dependent Claim
96 words
An articular cartilage xenograft for implantation into a human comprising a portion of an articular cartilage from a joint of a non-human animal, wherein the portion includes an extracellular matrix and a plurality of substantially only dead cells, the extracellular matrix and the dead cells having substantially no surface α-galactosyl moieties and having a plurality of sialic acid molecules linked to at least a portion of a plurality of surface carbohydrate moieties on the xenograft, whereby the portion of the articular cartilage is substantially non-immunogenic and has substantially the same mechanical properties as the articular cartilage.
Claim 41
Dependent Claim
14 words
The articular xenograft of claim 35, wherein the portion has a bone layer substrate.
References Cited (Backward Citations)
US4034418A
Cited
US4344193A
Cited
US4400833A
Cited
US4502161A
Cited
US4502161B1
Cited
WO1984003036A1
Cited
US4642120A
Cited
US4801299A
Cited
US4609627A
Cited
US4932973A
Cited
US4789663A
Cited
US4597266A
Cited
US4678470A
Cited
US4627853A
Cited
US4755593A
Cited
US4776853A
Cited
US4846835A
Cited
US4880429A
Cited
US5007934A
Cited
US5306311A
Cited
US5158574A
Cited
US5078744A
Cited
US5071741A
Cited
US5171273A
Cited
US5116374A
Cited
US5067962A
Cited
US5171660A
Cited
US5131850A
Cited
US5092894A
Cited
US5171322A
Cited
US5306304A
Cited
US5192312A
Cited
US5160313A
Cited
US5216126A
Cited
US5507810A
Cited
US5358525A
Cited
US5613982A
Cited
WO1995026740A1
Cited
WO1995028412A1
Cited
WO1995033828A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2003-04-11 | 2003-10-11 | 2004-04-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2007-04-11 | 2007-10-11 | 2008-04-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2011-04-11 | 2011-10-11 | 2012-04-11 | $7700.00 | Window Closed / Lapsed |